When Kite Pharma's CMO spoke to Pharcilitate in December 2016, he noted that checkpoint inhibition can play a role in curtailing the effects of CAR-T therapy. Similarly, Novartis who is another major CAR-T player, is focused on major mechanisms of immune escape.
Myc is implicated in immune escape and helping cancer hide refer thread Everyone's talking IO but remember Myc. A successful therapy targeting Myc may provide an ideal combination with CAR-T therapy.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.27 |
Change
-0.020(1.56%) |
Mkt cap ! $737.8M | |||
| Open | High | Low | Value | Volume |
| $1.29 | $1.29 | $1.25 | $4.616M | 3.649M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 19940 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.27 | 1008 | 1 |
View Market Depth
| Last trade - 16.10pm 26/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |